A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer
Latest Information Update: 04 Nov 2021
At a glance
Most Recent Events
- 26 Jan 2021 Status changed from active, no longer recruiting to discontinued(The study was terminated due to lack of efficacy).
- 20 May 2020 Planned End Date changed from 1 Nov 2022 to 1 Dec 2021.
- 20 May 2020 Status changed from recruiting to active, no longer recruiting.